The underlying mechanism of scorpion venom peptide BmK AS in lowering epilepsy seizures: mediated by twin modulation of Nav1.6 and the inflammasome pathway
Summary
Introduction:
Voltage-gated sodium channel (VGSC) dysregulation, notably of the Nav1.6 subtype, is a core mechanism underlying epileptogenesis and its related neuropsychiatric comorbidities. The scorpion venom peptide BmK AS has demonstrated anticonvulsant potential, however its efficacy in persistent epilepsy and the exact mechanisms of motion stay undefined.
Strategies:
Right here, we present that BmK AS exerts sturdy anti-epileptic and neuroprotective results by converging mechanisms. In a kainic acid-induced mouse mannequin, BmK AS therapy diminished mortality and seizure parameters. Electrophysiological research assessed BmK AS modulation of VGSC subtypes. The useful relevance of Nav1.6 concentrating on was confirmed by the lack of BmK AS’s anti-seizure efficacy upon its pharmacological blockade in a PTZ-induced mannequin. Moreover, in each KA-induced persistent epilepsy fashions and native hippocampal neurons, BmK AS was evaluated for neuronal hyperexcitability and NLRP1 inflammasome-mediated pyroptosis.
Outcomes:
BmK AS diminished mortality to 0% (vs. 40% within the mannequin group) and considerably diminished seizure length by 10.5% and the frequency of extreme (levels 4 and 5) seizures by 68.8%. It additionally improved cognitive and psychiatric outcomes, considerably reversing epilepsy-associated spatial reminiscence deficits and anxiety-/depression-like behaviors. Electrophysiological research present that BmK AS nonlinearly inhibited a number of VGSC subtypes, with pronounced efficiency towards Nav1.6, lowering the height sodium present to 43% of management at 5 nM. BmK AS attenuated neuronal hyperexcitability and suppressed neuroinflammation by inhibiting the NLRP1 inflammasome pathway and the related pyroptosis.
Dialogue:
Our findings set up BmK AS as a promising multimechanistic therapeutic candidate, highlighting the strategic worth of twin therapeutic actions, particularly, Nav1.6 modulation and neuroinflammation inhibition, for epilepsy therapy.
